

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Outcome of the Protocol for Prevention of Mother to Child Transmission of Hepatitis B Infection and Nine Months Follow-up of Hepatitis B-exposed Infants at Ile-Ife, Nigeria.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-063482
Article Type:	Original research
Date Submitted by the Author:	01-Apr-2022
Complete List of Authors:	Ndububa, Dennis; Obafemi Awolowo University, Department of Medicine Kuti, Oluwafemi; Obafemi Awolowo University, Department of Obstetrics, Gynaecology and Perinatology Awowole, Ibraheem; Obafemi Awolowo University, Obstetrics, Gynaecology and Perinatology; Obafemi Awolowo University Teaching Hospital Complex, Obstetrics, Gynaecology and Perinatology Adekanle, Olusegun; Obafemi Awolowo University, Department of Medicine Ijarotimi, Oluwasegun; Obafemi Awolowo University, Department of Medicine Makinde, Olufemiwa; Obafemi Awolowo University, Department of Obstetrics, Gynaecology and Perinatology Adeyemi, Adebajo B; Obafemi Awolowo University, Department of Obstetrics, Gynaecology and Perinatology Anyabolu, Chineme; Obafemi Awolowo University, Department of Paediatrics and Child Health Ijadunola, Macellina; Obafemi Awolowo University, Department of Community Health
Keywords:	Adult gastroenterology < GASTROENTEROLOGY, Hepatobiliary disease < GASTROENTEROLOGY, Fetal medicine < OBSTETRICS, Maternal medicine < OBSTETRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Outcome of the Protocol for Prevention of Mother to Child Transmission of Hepatitis B**
4 **Infection and Nine Months Follow-up of Hepatitis B-exposed Infants at Ile-Ife, Nigeria.**
5

6
7 Dennis Ndububa; Department of Medicine, Obafemi Awolowo University, Ile-Ife, Osun State,
8 Nigeria. dennisandububa@yahoo.co.uk.
9

10
11 Oluwafemi Kuti: Department of Obstetrics, Gynaecology and Perinatology, Obafemi Awolowo
12 University, Ile-Ife, Osun State, Nigeria. okuti_victory@yahoo.com
13

14
15 Ibraheem Awowole: Department of Obstetrics, Gynaecology and Perinatology, Obafemi
16 Awolowo University, Ile-Ife, Osun State, Nigeria. iawowole@oauife.edu.ng
17

18
19 Olusegun Adekanle: Department of Medicine, Obafemi Awolowo University, Ile-Ife, Osun State,
20 Nigeria. olusegunadekanle@oauife.edu.ng
21

22
23 Oluwasegun Ijarotimi: Department of Medicine, Obafemi Awolowo University, Ile-Ife, Osun
24 State, Nigeria. segjarot@hotmail.com
25

26
27 Olufemiwa Makinde: Department of Obstetrics, Gynaecology and Perinatology, Obafemi
28 Awolowo University, Ile-Ife, Osun State, Nigeria. niyimakinde20022003@yahoo.com.
29

30
31 Adebajo Adeyemi: Department of Obstetrics, Gynaecology and Perinatology, Obafemi Awolowo
32 University, Ile-Ife, Osun State, Nigeria. babloola@yahoo.com
33

34
35 Chineme Anyabolu: Department of Paediatrics and Child Health, Obafemi Awolowo University,
36 Ile-Ife, Osun State, Nigeria.
37

38
39 Macellina Ijadunola: Department of Community Health, Obafemi Awolowo University, Ile-Ife,
40 Osun State, Nigeria. yjadun@oauife.edu.ng
41

42
43
44 **Corresponding Author:**

45
46 Ibraheem O. Awowole (FWACS, MRCOG)

47
48 Perinatology Unit, Department of Obstetrics, Gynaecology and Perinatology,

49
50 Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria.220005.

51
52 +2348033767719, iawowole@oauife.edu.ng
53

Abstract

Objectives: Eliminating Mother-to-Child-Transmission (MTCT) of Hepatitis B Virus (HBV) is central to the WHO's target of reducing hepatitis B infection in children to <0.1% by 2030. While Nigeria alone accounts for 8.3% of the global burden, interventional studies on prevention of MTCT of HBV are hardly available. This study aims to assess the impact of prevention of MTCT interventions on vertical transmission of HBV among pregnant women in Nigeria.

Design: A prospective cohort study

Setting: A University Teaching Hospitals Complex in Nigeria between 2015-2021.

Participants: 10,866 pregnant women and their pre-existing children.

Interventions: The pregnant women were screened for HBsAg using chromatographic immunoassay (Micropoint®, USA). HBsAg-positive women had the HBV panel assay done and their pre-existing children were screened. Women with HBV DNA $\geq 200,000$ IU/ml and those positive for HBeAg had 300mg daily of Tenofovir Disoproxil Fumarate (TDF) in the 3rd trimester. The newborns had HBV vaccines and HB Immunoglobulin (HBIG) administered, followed by testing for HBsAg at 9months postnatally.

Primary outcome measures: Prevalence of chronic hepatitis B infection in pregnancy, and the incidence of MTCT of HBV.

Results: Overall, 395 women had chronic HBV infection, giving a prevalence of 3.64%. Their mean age was 31.51 ± 5.71 years, with a median parity of 1.2. Thirteen women (3.3%) were positive for HBeAg, seven (3.1%) of the 225 pre-existing hepatitis B-exposed children were HBsAg positive, and 17 women had prenatal TDF. Overall, 376 women completed the study, with mean birthweight of 3.21 ± 1.86 kg and perinatal mortality rate of 29.2/1,000births. HBV vaccine-HBIG combination was administered to 260 newborns, while the others had HBV vaccine alone. All the children tested negative to the HBsAg at 9months.

Conclusion: Eliminating MTCT of hepatitis B infection through validated protocols in LMICs with the highest burden of chronic HBV infections is feasible. A national scale-up of such protocols is recommended.

Article Summary

Strengths and limitations of this study

- This study involves the largest cohort of hepatitis B pregnant women to be prospectively recruited and actively managed in Nigeria.
- The multidisciplinary nature of the study of the managing team made implementation of the hepatitis B EMTCT interventions feasible.
- This research is the only study to actively intervene, prospectively follow up and report the outcomes of hepatitis B exposed children till the age of 9 months in Nigeria.
- HBV DNA assay could not be routinely done in the HBsAg-positive women due to financial constraints.

Keywords: Chronic hepatitis B, Hepatitis B virus, Hepatitis B vaccine, Hepatitis B immunoglobulin, Mother-to-child transmission, Nigeria

Word count: 3,193

Introduction

The World Health Organization (WHO) estimates that 1.4 million deaths are recorded annually due to viral hepatitis, and hepatitis-associated mortality now ranks as the 7th leading cause of death globally, ahead of deaths due to HIV/AIDS, Malaria and Tuberculosis. This burden is mainly associated with Hepatitis B virus (48%), Hepatitis C virus (48%) and the remaining from acute hepatitis A and E infection¹. Overall, about 2 billion people are estimated to have evidence of past or present hepatitis B infection, and at least 296 million people, corresponding to about 3.8% of the global population are estimated to be chronically infected with the hepatitis B virus in 2019¹. The burden of hepatitis B infection is however unevenly distributed, with developing countries, especially the African and the Western Pacific regions suffering disproportionately; the 2 regions account for 67% of the global burden of hepatitis B infection¹⁻³, with at least 5% of the population estimated to be living with the hepatitis B infection. Worse still, the current figures are possibly

1
2
3 underestimates, as probably less than 5% of people that are chronically infected in these regions
4 have undergone testing to diagnose their status³.
5
6

7 Transmission of hepatitis B virus may be horizontal (through contact with body fluids including
8 blood, semen, and sharp objects) or vertical, through mother to child transmission. Vertical
9 transmission has served as a means of maintaining the reservoir of infection in low-and middle-
10 income countries, due to its propensity to progress into chronicity. While acute hepatitis B
11 infections in adults are likely to be cleared within 6months in 95% of cases, chronicity is recorded
12 in 20-60% of children under the age of 5years, and at least 90% of perinatally transmitted cases.
13 As these newborns often remain asymptomatic, diagnosis is unlikely until they reach the stage of
14 hepatic decompensation, liver cirrhosis or hepatocellular carcinoma (HCC) in adulthood.
15
16
17
18
19
20

21 The Center for Disease Control (CDC) estimated the prevalence of chronic hepatitis B infection
22 in Nigeria to be at least 8%⁴. This was further supported by the Federal Ministry of Health's
23 estimate of 11.1%, amounting to 8.3% of the global chronic hepatitis B infection, thereby making
24 Nigeria the country with the highest burden globally⁵. Despite the need to strive to attain the set
25 targets for Elimination of Mother to Child Transmission (EMTCT) of hepatitis B infection, and
26 the proven benefits of the afore-mentioned interventions, they are not always provided as standard
27 components of the Reproductive, Maternal, Newborn and Child Health (RMNCH) programmes in
28 Nigeria and other developing countries. A case in-point is the birth dose of hepatitis B vaccine
29 coverage, which is reported to be only 6% in the African region in 2020⁶. Although the HBV
30 vaccine is administered at no cost to newborns in Nigeria, only 52.4 % of Nigerian children
31 reportedly had the birth dose of hepatitis B vaccine, while just 4% had the dose administered within
32 the first 24hours of life as recommended, and overall, only 50.3% of Nigerian children completed
33 the 3 additional doses of hepatitis B vaccine⁷.
34
35
36
37
38
39
40
41
42
43
44

45 In response to the bothersome statistics of hepatitis B infection, the Global Health Sector Strategy
46 (GHSS) on viral hepatitis was launched at the World Health Assembly in 2016, with the aim of
47 eliminating viral hepatitis B and C infections⁸. For this goal of eliminating viral hepatitis as a
48 public health threat to be achieved, WHO has set the target of reducing HBsAg prevalence in
49 children to 0.1% by 2030⁸. To evaluate the impact of the EMTCT measures and identify
50 bottlenecks to the successful attainment of the GHSS targets in Low- and Middle-Income
51 Countries (LMICs) such as Nigeria, appropriately designed prospective studies are imperative.
52
53
54
55
56
57
58
59
60

1
2
3 Although some Nigerian researchers have evaluated the outcomes of pregnancies among women
4 with hepatitis infection, many of these studies were either retrospectively conducted or simply
5 prevalence studies that did not control for or report the quality of prevention of mother to child
6 transmission of hepatitis B care that the study subjects received^{9, 10}; none had therefore reported
7 on the outcome of implementing a well designed and implemented protocol. While Onakewhor et
8 al reported the administration of hepatitis B vaccine and HBIG immunoprophylaxis for PMTCT
9 among a Nigerian cohort, the study had a sample size of only 45 patients¹¹. This study was therefore
10 designed to meticulously implement the EMTCT of hepatitis B measures, and to follow the
11 hepatitis B-exposed babies till the age of 9 months, for the purpose of identifying perinatal vertical
12 and early childhood horizontal transmissions.
13
14
15
16
17
18
19
20

21 **Methods**

22
23 **Study setting:** The study was undertaken at the Perinatal Unit of the Department of Obstetrics,
24 Gynaecology and Perinatology, and the Gastroenterology Unit of the Department of Medicine,
25 Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria between
26 November 2015 and March 2021.
27
28
29
30

31 **Design:** The study is a prospective cohort study.
32

33 **Study participants:** All pregnant women that booked for antenatal care at the institution were
34 prospectively recruited for the study after appropriate counseling.
35
36

37 **Patient and public involvement:** It was not possible to involve patients in the design and conduct
38 of the study, but they will be involved in the dissemination of the study findings, for ease of
39 widespread dissemination.
40
41
42

43 **Ethics Approval:** Research approval for the study was obtained from the Obafemi Awolowo
44 University Teaching Hospitals Complex Ethics and Research Board (IRB/IEC/0004553:
45 ERC/20/02/010).
46
47
48

49 **Intervention:** After obtaining informed consent from each study participant, relevant data
50 regarding the socio-demographic characteristics of the women were captured using a purpose-
51 designed proforma. Provider-initiated counselling and testing of the participants' serum for
52 HBsAg was thereafter undertaken, using chromatographic immunoassay (Micropoint®, USA)
53
54
55
56
57
58
59
60

1
2
3 rapid diagnostic kit. Women who tested positive subsequently had the complete hepatitis B viral
4 panel assay done, comprising the Hepatitis B surface Antibody (HBsAb), Hepatitis B core
5 antibody (HBcAb: Total and IgG). Hepatitis B e-antigen (HBeAg) and the Hepatitis B e-antibody
6 (HBeAb), using Micropoint® kit, for the purpose of categorization and prognostication. To ensure
7 compliance, the cost of the complete hepatitis B viral panel assay was subsidized significantly by
8 the research team. Serum hepatitis B viral DNA assay was also routinely requested for all the
9 HBsAg positive patients. Chronic Hepatitis B (CHB) infection was defined as the presence of
10 HBsAg for more than 6 months in the participants, or the presence of the IgG fraction of the
11 Hepatitis B core antibody, with absent HBsAb and IgM fraction. All the pregnant women
12 diagnosed with CHB were encouraged to bring their pre-existing children for testing and those
13 identified as HBsAg positive were referred for necessary treatment at the Paediatric and Child
14 Health Department of the hospital. Three categories of women were considered for antenatal
15 treatment with Tenofovir Disoproxil Fumarate (TDF), namely, those with serum HBV DNA \geq
16 200,000iu/ml, women positive for HBeAg without serum HBeAb, and women with history of
17 perinatal transmission in their previous pregnancies. Pregnant women in any of these categories
18 were placed on TDF 300mg orally once daily starting from the 28th week of gestation till delivery.
19 The mode of delivery was determined strictly by obstetric indications. Serial phone calls were
20 placed to all the study participants as their pregnancies advanced, to ensure compliance with
21 antenatal care and postpartum EMTCT of hepatitis B advisories. Those who delivered out-of-
22 facility were therefore identified and necessary EMTCT of hepatitis B measures were implemented
23 without delay. All the babies that were delivered within the study period, irrespective of the place
24 of birth or the day of the week, had the birth dose of the hepatitis B vaccine administered within
25 24hours of delivery. When affordable to the patient, 200iu of the Hepatitis B Immunoglobulin
26 (HBIG) was also administered to the newborns of the hepatitis B positive parturients within
27 24hours of delivery, while the mothers were referred to the Gastroenterology Unit for continuity
28 of care. All the babies were followed up on phone to ensure strict compliance with the national
29 vaccination schedule, including the hepatitis B vaccination. The infants were tested at the age of
30 9months, to assess their hepatitis B infection status. The primary outcome measure was the
31 proportion of infants that tested positive to the HBsAg at the age of 9months. Secondary outcomes
32 were the proportion of hepatitis-B exposed babies that had the birth dose of hepatitis B vaccine
33 within 24hours, the proportion of babies that completed the 3doses of the hepatitis B vaccine at
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the appropriate time, spontaneous miscarriage rate, preterm delivery rate, mean birthweight and
4 the perinatal mortality rate of the hepatitis B-exposed infants.
5
6

7 **Results**

8
9 A total of 10,866 pregnant women were screened during the study period, of which 395 tested
10 positive to the HBsAg, giving a prevalence of 3.64%. The mean age of the women was $31.51 \pm$
11 5.71 years, with a median parity of 1.2. More than half (53.9%) were screened before the 28th week
12 of pregnancy, and 249 women (63%) had the complete hepatitis B viral antibody assay done. The
13 remaining expectant mothers (146:37%) could not do the complete hepatitis B viral serology due
14 to financial constraints. All the HBsAg positive had chronic hepatitis B infection. In addition, 13
15 (3.3%) of the 395 positive women expressed HBeAg in their serum, while 162 women (41%) had
16 developed the anti-HBe antibody. Three patients had both the HBeAg and the HBeAb
17 contemporaneously. Of the 225 pre-existing hepatitis-B exposed children before the index
18 pregnancy that were tested, seven (3.1%) were HBsAg positive. Seventeen women had prenatal
19 TDF administered from 28 weeks gestation till delivery.
20
21
22
23
24
25
26
27
28

29 Of the 395 women that tested positive to the HBsAg, there was one spontaneous miscarriage, while
30 18 patients were lost to follow-up. Further analysis was therefore based on 376 women that
31 completed the study with known perinatal outcomes. With respect to mode of delivery, 219 women
32 (58.2%) had spontaneous vaginal delivery, with a Caesarean section rate of 41.8%. The mean birth
33 weight of the babies was 3.21 ± 1.86 kg. Forty women (10.2%) had preterm births, defined as
34 spontaneous or provider-initiated delivery for obstetric reasons, before 37 completed weeks, and
35 there were 11 perinatal mortalities (comprising six stillbirths and five early neonatal deaths), with
36 a stillbirth rate of 15.9/1,000 births and a perinatal mortality rate of 29.2/1,000 births. All the babies
37 were breastfed (Figure 1: Flow chart of study protocol).
38
39
40
41
42
43
44

45 Hepatitis B Vaccine-Birth Dose (HBV-BD) was administered to all the 365 newborns; 327 babies
46 (89.6%) had the HBV-BD administered within 24 hours of delivery, while the remaining 38 babies
47 (10.4%) had delayed vaccination within 2-4 days postpartum due to logistic reasons. There was a
48 diarrhoea-related infant mortality among the cohort, leaving 364 babies (99.7%) that completed
49 the HBV-3 at the appropriate time. In addition, 260 (71.3%) babies had both HBV vaccine and the
50 Hepatitis B immunoglobulin combination; the remaining 105 babies (28.7%) did not have the
51 HBIG administered due to financial constraints. The entire hepatitis-B exposed cohort of 364
52
53
54
55
56
57
58
59

1
2
3 children tested HBsAg negative at the exit hepatitis B screening that was conducted between 9-10
4 months postnatally.
5
6

7 **Discussion**

8
9
10 In 2020, the WHO Interim guidance for country validation of viral hepatitis elimination was
11 launched, with absolute targets that include HBsAg prevalence $\leq 0.1\%$ in those aged 5 years or
12 less, 95% reduction in mother to child transmission rates and an absolute hepatitis B related annual
13 mortality rate of <4 per 100,000 persons. To achieve this, each country is expected to target at least
14 90% coverage of maternal antenatal HBsAg testing, $\geq 90\%$ coverage with antivirals for those
15 eligible, 90% timely HBV vaccine birth dose (HBV-BD), and $\geq 90\%$ of 3 doses (HepB3) vaccine
16 coverage¹. This vaccination is expected to confer immunity on at least 95% of the vaccinated
17 infants. Co-administration of hepatitis B immunoglobulin (HBIG) may also be used to further
18 reduce the risk of MTCT of HBV. This study met all the set targets, with absolute prevention of
19 vertical and early childhood transmission of hepatitis B virus up to the age of 9 months among the
20 cohort. This conforms to the findings of some studies that had earlier reported 0% transmission
21 rate following initiation of immunoprophylaxis within 24 hours of birth^{11,12}. Meanwhile, seven
22 (3.1%) of the 225 already existing children that were delivered to the same cohort of women before
23 the commencement of this protocol tested positive to the hepatitis B virus during screening. This
24 further underpins the immense role of the hepatitis B preventative measures at eliminating vertical
25 transmission.
26
27

28
29
30 Expression of HBeAg significantly heightens the risk of vertical transmission of HBV. In a
31 systematic review of 15 articles from 11 African countries including Nigeria by Keane et al, the
32 pooled risks of vertical transmission of hepatitis B virus among 34 HBeAg positive mothers was
33 38.3% (95% CI: 7.0–74.4%) without prophylaxis, and 4.8% (95% CI: 0.1–13.3%) among HBeAg
34 negative mothers, without prophylaxis. These rates are similar to the 40% and 5% transmission
35 rates for HBeAg-positive and -negative mothers respectively, by WHO (3) This risk was however
36 eliminated among the 13 HBeAg positive women in the index study due to the combination of
37 prenatal TDF from the 28th week of gestation and postpartum prophylaxis in the exposed children.
38 This approach has been proven to be more effective than vaccination at birth alone, among HBeAg
39 positive mothers, at preventing vertical transmission^{3,13}. Prenatal TDF is already supplied to HIV
40 positive patients at no cost. Such privilege is, however, not yet available to HBV positive
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 women^{11,14}. It is advisable that the country leverages on the supply chain that is already available
4 for HIV PMTCT programmes, for the prevention of HBV as well.

5
6 Almost 30% of the children in this study did not have the HBIG administered due to financial
7 constraints. This is not unexpected, as such medications are expensive and only available on an
8 “out-of-pocket” payment basis, and according to the World Bank and the National Bureau of
9 Statistics (NBS) of Nigeria, about 40% of Nigeria’s population, amounting to about 83 million
10 people, live below the country’s poverty line of \$381.75 per annum¹⁵. There was, however, no
11 difference in the outcome of the children in the Hepatitis B vaccine-HBIG combination and the
12 hepatitis B vaccine alone groups. This observation aligns with an earlier report that the efficacy of
13 appropriately administered HepB3 is comparable to that of HBV vaccine-HBIG combination¹⁶,
14 and the WHO recommendation of HepB3 as the primary preventative measure for hepatitis B-
15 exposed children, with expected immunity rate of 95%. This finding is of significant relevance,
16 especially in low- and Middle-income countries such as Nigeria, where a dose (200iu) of HBIG as
17 at the time of the study costs about 70,000 Naira, equivalent to 166 US Dollars. Meanwhile, the
18 HBV vaccine is made available free to all newborns as a national policy through governmental
19 efforts in Nigeria and many of the developing countries. The use of HBV vaccine is recorded to
20 have prevented 210million new chronic infections so far, with over a million deaths averted within
21 the next 8years. It is therefore essential that health care facilities and systems in LMICs, including
22 Nigeria prioritize achievement of the set targets for HBV-BD and HepB3, to maximize the benefits
23 from the already existing governmental policies. Without doing this, however, about 63 million
24 new chronic infections and 17million deaths could be recorded within the same period¹⁷.

25
26 With respect to obstetric outcomes, the prematurity rate is comparable with the report for the
27 general obstetric population. The Caesarean section rate was comparable to the 47% reported from
28 an earlier study, and the mean birthweight was also comparable to the 3210 ± 490g reported by
29 Awowole et al from the same center 3 years earlier¹⁸. Hepatitis B infection in pregnancy was not
30 associated with increased stillbirth or perinatal mortality rate among the cohort in this study, as the
31 findings were comparable to the stillbirth rate of 15/1,000 births recorded by Kuti et al among
32 unselected booked patients at the same facility¹⁹. The perinatal mortality rate of 29.2/1,000 births
33 from this study, though high, is comparable to the perinatal mortality rate of 38/1,000 births
34 reported by the Nigerian Demographic and Health Survey for the southwest geopolitical zone,
35 where the OAUTHC is situated⁷. Chronic asymptomatic hepatitis B infection in pregnancy was
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 therefore not associated with increased Caesarean section, low birth weight, stillbirth, and perinatal
4 mortality rates in this study.
5

6
7 The mother to child transmission of hepatitis B infection rate of 0% at 9 months in this study is
8 comparable to the findings from some earlier studies that reported similar transmission rates,
9 following initiation of the HBV-BD within 24hours of delivery^{11,12,14}. Meanwhile, seven (3.1%)
10 of the 225 children delivered to the same cohort of women before the commencement of this
11 protocol tested positive to the hepatitis B virus during screening. This further underpins the
12 immense role of the hepatitis B preventative measures at eliminating vertical transmission.
13
14

15
16 One of the strengths of this study is the sample size, which involves the largest cohort of hepatitis
17 B pregnant women to be prospectively recruited and actively managed in Nigeria, translating to
18 generation of reliable and credible data. The multidisciplinary nature of the study, with
19 involvement of Specialists from Obstetrics, Gastroenterology, Paediatrics and Child Health, Public
20 Health and the Childhood Immunization Sub-unit and Community Health Extension Workers
21 made in-facility and community monitoring, surveillance, and painstaking implementation of the
22 hepatitis B EMTCT interventions feasible in the study cohort. This research is also the only study
23 in Nigeria, to prospectively follow up and report the outcomes of hepatitis B exposed children till
24 the age of 9months, following implementation of HBV EMTCT measures. In addition, this is the
25 first study from Nigeria that endeavored to screen all the pre-existing children of hepatitis B
26 pregnant women, with appropriate follow-up at the Paediatric and Child Health Unit of the
27 Teaching Hospital, thereby using the antenatal period as a window of opportunity to provide a
28 family-centered, holistic care to the affected women.
29
30
31
32
33
34
35
36
37
38
39
40

41 This study also has some identifiable limitations. Since 2020, WHO has updated its
42 recommendation to include the administration of TDF to pregnant women with HBV DNA
43 $\geq 200\ 000$ IU/mL to prevent mother-to-child transmission (PMTCT) of HBV^{1,20}. One of the
44 limitations of this study is however the inability to undertake the quantitative HBV DNA in all the
45 women due to financial constraints This, however, did not significantly affect the outcome of the
46 study. Secondly, the additional benefit of HBIG among HBV-positive women in low-resource
47 settings could have been better assessed using a randomized controlled trial. Withholding such
48 treatment from the control group, especially for patients that could afford it would however have
49 been unethical. It is also not clear whether the pre-existing children that tested positive to the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 hepatitis B virus acquired the infections at birth or in early childhood. Discerning this may however
4 not be significant, as the endpoint of chronic childhood hepatitis B infection are similar. Lastly,
5 screening for anti-HBs titre has been recommended for HBsAg-negative infants as anti-HBs levels
6 ≥ 100 mIU/ml are considered protective with no need for further medical management²¹. Screening
7 for anti-HBs was not done in this study for the 364 babies that were HBsAg-negative at 9 months
8 of age due to financial constraints.
9

10
11
12
13
14 In conclusion, this study demonstrates that achieving the set goals for eliminating mother to child
15 transmission of hepatitis B infection is feasible, even in the absence of high-end investigations
16 such as HBV DNA assay, and expensive interventions such as the HBIG, especially in LMICs
17 with the highest burden of chronic HBV infections and limited resources. Chronic hepatitis B
18 infection did not demonstrate adverse effect on the outcome of the pregnancies. A national scale-
19 up of these interventions in Nigeria through committed vaccination policies, sustained
20 governmental funding and commitment, as well as universal health coverage are required to bridge
21 the gap for the patients that live below poverty line in Nigeria and would therefore not be able to
22 afford even the most basic of these interventions.
23
24
25
26
27
28
29

30 **Author Contributions:** DN and OK conceived the study. IA, OA, OI participated in literature
31 search and proposal writing. All the authors participated in study design, supervision of sample
32 collection, patient management, critical review of the manuscript for intellectual content, and
33 approval of the final draft and agree to take responsibility for the integrity of the research.
34
35
36
37

38 **Data sharing statement:** The raw data for this study is available
39

40 **Funding:** This research received no specific grant from any funding agency in the public,
41 commercial or not-for-profit sectors.
42
43

44 **Competing interests:** All the authors hereby declare no competing interests.
45
46

47 **Acknowledgements:** The research team wishes to acknowledge the immense contributions of
48 Matron Lawal G.O, Mrs Morakinyo, Mrs Omiwole O. and Miss Olaiwon S. to the successful
49 completion of this research.
50
51
52
53
54
55
56
57
58
59
60

References

1. World Health Organization. Interim guidance for country validation of viral hepatitis elimination. Geneva: World Health Organization; 2021.
2. World Health Organization. Regional Action Plan for Viral Hepatitis in the Western Pacific 2016–2020. Geneva: World Health Organization; 2016.
3. World Health Organization. Global Hepatitis Report, 2017. Geneva: World Health Organization; 2017.
4. Center for Disease Control. Global Viral Hepatitis: Millions of People are Affected. 2021: Available at <https://www.cdc.gov/hepatitis/global/index.htm>.
5. Federal Ministry of Health Nigeria. National Guidelines for the Prevention, Treatment and Care of Viral Hepatitis in Nigeria. FMOH; Abuja: Nigeria; 2016.
6. Breakwell L, Tevi-Benissan C, Childs L, Mihigo R, Tohme R. The status of hepatitis B control in the African region. *Pan Afri Med J.* 2017;27:17.
7. National Population Commission (NPC) [Nigeria] and ICF. Nigeria DHS Key Findings. Abuja, Nigeria and Rockville, Maryland, USA: National Population Commission; 2019.
8. World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2021: Towards Ending Viral Hepatitis. Geneva: World Health Organization; 2016.
9. Mbaawuaga EM, Enenebeaku MNO, Okopi JA, Damen JG. Hepatitis B Virus (HBV) Infection among Pregnant Women in Makurdi, Nigeria. *Afri J Biomed Res.* 2008;11:155-9.
10. BT Utoo. Hepatitis B surface antigenemia (HBsAg) among pregnant women in southern Nigeria. *Afri Health Sci.* 2013;13(4):1139-43.

11. Onakewhor JUE, Charurat M, Matthew O, Osagie E, Asemota MO, Omoigberale A. Serologic Pattern of Hepatitis B Infection among Exposed and Non-Exposed Babies in A PMTCT Program in Low Resource Setting: Does Every Exposed Newborn Require 200IU of Hepatitis B Immunoglobulin? *J Vaccines Vaccin.* 2013;4:7.
12. Keane E, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. *Aliment Pharmacol Ther.* 2016;44:1005-17.
13. Brown RS Jr, McMahon BJ, Lok ASF, Wong JB, Ahmed AT, Mouchli MA, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. *Hepatology.* 2016;63(1):319-33.
14. Ekraa D, Herbingerb K, Konatec S, Leblond A, Fretz C, Ciloteb V, et al. A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Côte d'Ivoire. *Vaccine.* 2008;26 (22):2753-61.
15. The World Bank. Nigeria releases new report on poverty and inequality in country: 2021. Available at <https://www.worldbank.org/en/programs/lsm/brief/nigeria-releases-new-report-on-poverty-and-inequality-in-country>.
16. Lolekha S, Warachit B, Hirunyachote A, Bowonkiratikachorn P, West DJ, Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBsAg-positive carrier mothers in Thailand. *Vaccine.* 2002;3739-43.
17. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. *Lancet Infect Dis* 2016;16:1399-408.
18. Awowole IO, Kuti O, Asaleye CM, Badejoko OO, Bola-Oyebamiji SB, Olatunji RB, et al. Normative References and Clinical Correlates of Fetal Umbilical Artery Doppler Indices in Southwestern Nigeria. *Int J Gynaecol Obstet.* 2020;151:134-40.
19. Kuti O, Awowole IO, Okunola TO. Audit of stillbirths in a Nigerian teaching hospital. *Trop J Obstet Gynaecol.* 2017;34(3):188-94.
20. World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization; 2020.

1
2
3 21. Hou J, Cui F, Ding Y, Dou X, Duan Z, Han G et al. Management Algorithm for Interrupting
4 Mother-to-Child Transmission of Hepatitis B Virus. *Clinical Gastroenterology and Hepatology*,
5 2019; 17: 1929 – 1936.
6
7

8
9 **Figure Legend**
10

11 **Figure 1:** Figure 1: Flow chart of study protocol
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Flow chart of study protocol

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	4
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	6
		(d) If applicable, explain how loss to follow-up was addressed	7
		(e) Describe any sensitivity analyses	NA
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	Yes
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6
		(b) Indicate number of participants with missing data for each variable of interest	6
		(c) Summarise follow-up time (eg, average and total amount)	6
Outcome data	15*	Report numbers of outcome events or summary measures over time	6
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	6
Discussion			
Key results	18	Summarise key results with reference to study objectives	7
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	7
Generalisability	21	Discuss the generalisability (external validity) of the study results	8
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	10

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Prospective Cohort Study of Prevention of Mother to Child Transmission of Hepatitis B Infection and Nine Months Follow-up of Hepatitis B-exposed Infants at Ile-Ife, Nigeria.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-063482.R1
Article Type:	Original research
Date Submitted by the Author:	19-Aug-2022
Complete List of Authors:	Ndububa, Dennis; Obafemi Awolowo University, Department of Medicine Kuti, Oluwafemi; Obafemi Awolowo University, Department of Obstetrics, Gynaecology and Perinatology Awowole, Ibraheem; Obafemi Awolowo University, Obstetrics, Gynaecology and Perinatology; Obafemi Awolowo University Teaching Hospital Complex, Obstetrics, Gynaecology and Perinatology Adekanle, Olusegun; Obafemi Awolowo University, Department of Medicine Ijarotimi, Oluwasegun; Obafemi Awolowo University, Department of Medicine Makinde, Olufemiwa; Obafemi Awolowo University, Department of Obstetrics, Gynaecology and Perinatology Adeyemi, Adebajo B; Obafemi Awolowo University, Department of Obstetrics, Gynaecology and Perinatology Anyabolu, Chineme; Obafemi Awolowo University, Department of Paediatrics and Child Health Ijadunola, Macellina; Obafemi Awolowo University, Department of Community Health
Primary Subject Heading:	Obstetrics and gynaecology
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	Adult gastroenterology < GASTROENTEROLOGY, Fetal medicine < OBSTETRICS, Maternal medicine < OBSTETRICS, Hepatobiliary disease < GASTROENTEROLOGY, PERINATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Prospective Cohort Study of Prevention of Mother to Child Transmission of Hepatitis B**
4 **Infection and Nine Months Follow-up of Hepatitis B-exposed Infants at Ile-Ife, Nigeria.**
5
6

7 Dennis Ndububa; Department of Medicine, Obafemi Awolowo University, Ile-Ife, Osun State,
8 Nigeria. dennisandububa@yahoo.co.uk.
9

10
11 Oluwafemi Kuti: Department of Obstetrics, Gynaecology and Perinatology, Obafemi Awolowo
12 University, Ile-Ife, Osun State, Nigeria. okuti_victory@yahoo.com
13

14
15 Ibraheem Awowole: Department of Obstetrics, Gynaecology and Perinatology, Obafemi
16 Awolowo University, Ile-Ife, Osun State, Nigeria. iawowole@oauife.edu.ng
17

18
19 Olusegun Adekanle: Department of Medicine, Obafemi Awolowo University, Ile-Ife, Osun State,
20 Nigeria. olusegunadekanle@oauife.edu.ng
21

22
23 Oluwasegun Ijarotimi: Department of Medicine, Obafemi Awolowo University, Ile-Ife, Osun
24 State, Nigeria. segjarot@hotmail.com
25

26
27 Olufemiwa Makinde: Department of Obstetrics, Gynaecology and Perinatology, Obafemi
28 Awolowo University, Ile-Ife, Osun State, Nigeria. niyimakinde20022003@yahoo.com.
29

30
31 Adebajo Adeyemi: Department of Obstetrics, Gynaecology and Perinatology, Obafemi Awolowo
32 University, Ile-Ife, Osun State, Nigeria. [baboolola@yahoo.com](mailto:babloola@yahoo.com)
33

34
35 Chineme Anyabolu: Department of Paediatrics and Child Health, Obafemi Awolowo University,
36 Ile-Ife, Osun State, Nigeria.
37

38
39 Macellina Ijadunola: Department of Community Health, Obafemi Awolowo University, Ile-Ife,
40 Osun State, Nigeria. yijadun@oauife.edu.ng
41

42
43
44 **Corresponding Author:**
45

46 Ibraheem O. Awowole (FWACS, MRCOG)

47 Perinatology Unit, Department of Obstetrics, Gynaecology and Perinatology,

48
49 Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria.220005.
50

51
52 +2348033767719, iawowole@oauife.edu.ng
53
54
55
56
57
58
59
60

Abstract

Objectives: Eliminating Mother-to-Child-Transmission (MTCT) of Hepatitis B Virus (HBV) is central to WHO's target of reducing hepatitis B infection in children to <0.1% by 2030. While Nigeria accounts for 8.3% of the global burden, interventional studies on prevention of MTCT of HBV are hardly available. This study aims aimed to assess the impact of prevention of MTCT interventions on vertical transmission of HBV among pregnant women in Nigeria.

Design: A prospective cohort study

Setting: A University Teaching Hospitals Complex in Nigeria between 2015-2021.

Participants: 10,866 pregnant women and their pre-existing children.

Interventions: Eligible pregnant women were screened for HBsAg using chromatographic immunoassay (Micropoint®, USA). HbsAg-positive women had HBV serological assay done and their pre-existing children were screened. Women with HBV DNA $\geq 200,000$ IU/ml and those positive for HBeAg had 300mg daily of Tenofovir Disoproxil Fumarate (TDF) in the 3rd trimester. The newborns had hepatitis B vaccines and HB Immunoglobulin (HBIG) administered, followed by testing for HBsAg at 9 months post-natally.

Primary outcome measures: Prevalence of chronic hepatitis B infection in pregnancy, and the incidence of MTCT of HBV.

Results: Overall, 395 women had chronic HBV infection, giving a prevalence of 3.64%. Their mean age was 31.51 ± 5.71 years, with a median parity of 1.2. Thirteen women (5.2%) were positive for HBeAg, seven (3.1%) of the 225 pre-existing hepatitis B-exposed children were HbsAg positive, and 17 women had prenatal TDF. Overall, 376 women completed the study, with mean birthweight of 3.21 ± 1.86 kg and perinatal mortality rate of 29.2/1,000 births. Hepatitis B vaccine-HBIG combination was administered to 260 newborns, while the others had hepatitis B vaccine alone. All the children tested negative to the HbsAg at 9 months.

Conclusion: Eliminating MTCT of hepatitis B virus infection through validated protocols in Low- and Middle-Income Countries (LMICs) with the highest burden of chronic HBV infections is feasible. National scale-up of such protocols is recommended.

Article Summary

Strengths and limitations of this study

- This study involves the largest cohort of hepatitis B pregnant women to be prospectively recruited and actively managed in Nigeria.
- The multidisciplinary nature of the study of the managing team made implementation of the hepatitis B EMTCT interventions feasible.
- This research is the only study to actively intervene, prospectively follow up and report the outcomes of hepatitis B exposed children till the age of 9 months in Nigeria.
- HBV DNA assay could not be routinely done in the HBsAg-positive women due to financial constraints.

Keywords: Chronic hepatitis B, Hepatitis B virus, Hepatitis B vaccine, Hepatitis B immunoglobulin, Mother-to-child transmission, Nigeria

Word count: 3,586

Introduction

The World Health Organization (WHO) estimates that 1.4 million deaths are recorded annually due to viral hepatitis, and hepatitis-associated mortality now ranks as the 7th leading cause of death globally, ahead of deaths due to HIV/AIDS, Malaria and Tuberculosis. This burden is mainly associated with Hepatitis B virus (48%), Hepatitis C virus (48%) and the remaining from acute hepatitis A and E infection¹. Overall, about 2 billion people are estimated to have evidence of past or present hepatitis B infection, and at least 296 million people, corresponding to about 3.8% of the global population ~~are~~ were estimated to be chronically infected with the Hepatitis B Virus (HBV) in 2019¹. The burden of hepatitis B infection is however unevenly distributed, with developing countries, especially the African and the Western Pacific regions suffering disproportionately; the 2 regions account for 67% of the global burden of hepatitis B infection¹⁻³, with at least 5% of the population estimated to be living with the hepatitis B infection.

1
2
3 Transmission of HBV may be horizontal (through contact with body fluids including blood, semen,
4 and sharp objects) or vertical, through mother to child transmission. Vertical transmission has
5 served as a means of maintaining the reservoir of infection in low-and middle-income countries
6 (LMIC), due to its propensity to progress into chronicity. While acute hepatitis B infections in
7 adults are likely to be cleared within 6 months in 95% of cases, chronicity is recorded in 20-60%
8 of children under the age of 5years, and at least 90% of perinatally transmitted cases. As these
9 newborns often remain asymptomatic, some diagnoses may only be made incidentally during
10 routine screening for blood donation, admissions into schools and blood donation. Others may
11 however not be diagnosed until they reach the stage of hepatic decompensation, liver cirrhosis or
12 hepatocellular carcinoma in adulthood.
13
14
15
16
17
18
19
20

21 The Center for Disease Control (CDC) estimated the prevalence of chronic hepatitis B infection
22 in Nigeria to be at least 8%⁴. This was further supported by the Federal Ministry of Health's
23 estimate of 11.1%, amounting to 8.3% of the global chronic hepatitis B infection, thereby making
24 Nigeria the country with the highest burden globally⁵. Despite the need to strive to attain the set
25 targets for Elimination of Mother to Child Transmission (EMTCT) of hepatitis B infection, and
26 the proven benefits of the afore-mentioned interventions, they are not always provided as standard
27 components of the Reproductive, Maternal, Newborn and Child Health (RMNCH) programmes in
28 Nigeria and other developing countries. A case in-point is the birth dose of hepatitis B vaccine
29 coverage, which is was reported to be only 6% in the African region in 2020⁶. Although the HBV
30 vaccine is administered at no cost to newborns in Nigeria, only 52.4 % of Nigerian children
31 reportedly had the birth dose of hepatitis B vaccine, while just 4% had the dose administered within
32 the first 24hours of life as recommended, and overall, only 50.3% of Nigerian children completed
33 the 3 additional doses of hepatitis B vaccine⁷.
34
35
36
37
38
39
40
41
42
43

44 In response to the bothersome statistics of hepatitis B infection, the Global Health Sector Strategy
45 (GHSS) on viral hepatitis was launched at the World Health Assembly in 2016, with the aim of
46 eliminating viral hepatitis B and C infections⁸. For this goal of eliminating viral hepatitis as a
47 public health threat to be achieved, WHO has set the target of reducing HBsAg prevalence in
48 children to 0.1% by 2030⁸. To evaluate the impact of the EMTCT measures and identify
49 bottlenecks to the successful attainment of the GHSS targets in LMICs such as Nigeria,
50 appropriately designed prospective studies are imperative. Although some Nigerian researchers
51
52
53
54
55
56
57
58
59
60

1
2
3 have evaluated the outcomes of pregnancies among women with hepatitis B virus infection, many
4 of these studies were either retrospectively conducted or simply prevalence studies that did not
5 control for or report the quality of prevention of mother to child transmission of hepatitis B care
6 that the study subjects received^{9, 10}; none had therefore reported on the outcome of implementing
7 a well designed and implemented protocol. While Onakewhor et al reported the administration of
8 hepatitis B vaccine and HBIG immunoprophylaxis for PMTCT among a Nigerian cohort, the study
9 had a sample size of only 45 patients¹¹. This study was therefore designed to meticulously
10 implement the EMTCT of hepatitis B measures, and to follow the hepatitis B-exposed babies till
11 the age of 9 months, for the purpose of identifying perinatal vertical and early childhood horizontal
12 transmissions.

21 **Methods**

22
23 **Study setting:** The study was undertaken at the Perinatal Unit of the Department of Obstetrics,
24 Gynaecology and Perinatology, and the Gastroenterology Unit of the Department of Medicine,
25 Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria between
26 November 2015, and March 2021.

27
28 **Design:** The study is a prospective cohort study.

29
30
31 **Study participants:** All consecutive pregnant women that booked for antenatal care at the
32 institution were prospectively recruited for the study after appropriate counseling. As the study
33 was descriptive without any hypothesis testing, a specific sample size wasn't calculated.

34
35
36 **Inclusion criteria:** All pregnant women that received antenatal care at the Obafemi Awolowo
37 University Teaching Hospitals Complex, Ife, Osun State, Nigeria during the study period.

38
39
40 **Exclusion criteria:** Pregnant women that refused to consent to HBV screening.

41
42
43 **Statistical analysis:** the data was analysed with IBM SPSS 20.0. Categorical variables were
44 presented in frequencies and percentages while continues variables were presented as means and
45 standard deviations.

46
47
48 **Patient and public involvement:** It was not possible to involve patients in the design and conduct
49 of the study, but they will be involved in the dissemination of the study findings, for ease of
50 widespread dissemination.

1
2
3 **Ethics Approval:** Research approval for the study was obtained from the Obafemi Awolowo
4 University Teaching Hospitals Complex Ethics and Research Board (IRB/IEC/0004553:
5 ERC/20/02/010).
6
7

8
9 **Intervention:** After obtaining informed consent from each study participant, relevant data
10 regarding the socio-demographic characteristics of the women were captured using a purpose-
11 designed proforma. Provider-initiated counselling and testing of the participants' serum for
12 HBsAg was undertaken for all consecutive pregnant women by the Nurses at the antenatal clinic,
13 using chromatographic immunoassay (Micropoint®, USA) rapid diagnostic kit. In addition to
14 HBsAg testing, all the women also had retroviral screening done after due counselling. HBsAg
15 positive women subsequently had the complete hepatitis B serological markers assay done,
16 comprising the Hepatitis B surface Antibody (HBsAb), Hepatitis B core antibody (HBcAb: Total
17 and IgG), Hepatitis B e-antigen (HBeAg) and the Hepatitis B e-antibody (HBeAb), using
18 Micropoint® kit, for the purpose of categorization and prognostication. To ensure compliance,
19 95% subsidy on the cost of the hepatitis B serological marker was provided by the research team.
20 HBV DNA assay was also routinely requested for all the HBsAg positive patients, but this was not
21 subsidised. Chronic Hepatitis B (CHB) infection was defined as the presence of HBsAg for more
22 than 6 months in the participants, or the presence of the IgG fraction of the Hepatitis B core
23 antibody, with absent HBsAb and IgM fraction. All the pregnant women diagnosed with CHB
24 were encouraged to bring their pre-existing children for testing and those identified as HBsAg
25 positive were referred for necessary treatment at the Paediatric and Child Health Department of
26 the hospital. Three categories of women were considered for antenatal treatment with Tenofovir
27 Disoproxil Fumarate (TDF), namely, those with serum HBV DNA $\geq 200,000$ IU/ml, women
28 positive for HBeAg without serum HBeAb, and women with history of perinatal transmission in
29 their previous pregnancies. Pregnant women in any of these categories were placed on TDF 300mg
30 orally once daily starting from the 28th week of gestation till delivery, or as soon as possible, if the
31 diagnosis was made after the 28th week of gestation. Adherence to medication was assessed during
32 outpatient follow-up by the Gastroenterologists, who were also members of the research team. The
33 mode of delivery was determined strictly by obstetric indications. Serial phone calls were placed
34 to all the study participants by dedicated research staff and community health workers as their
35 pregnancies advanced, to ensure compliance with antenatal care and postpartum EMTCT of
36 hepatitis B advisories. Those who delivered out-of-facility were therefore identified and necessary
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

EMTCT of hepatitis B measures were implemented without delay. All the babies that were delivered within the study period, irrespective of the place of birth or the day of the week, had the birth dose of the hepatitis B vaccine administered within 24 hours of delivery by the National Programme on Immunization (NPI) department. When affordable to the patient, 200iu of the Hepatitis B Immunoglobulin (HBIG) was also administered to the newborns of the hepatitis B positive parturients within 24 hours of delivery, while the mothers were referred to the Gastroenterology Unit for continuity of care. All the babies were followed up on phone to ensure strict compliance with the national vaccination schedule, including the hepatitis B vaccination. The infants were tested at the age of 9 months, to assess their hepatitis B infection status. The primary outcome measure was the proportion of infants that tested positive to the HBsAg at the age of 9 months. Secondary outcomes were the proportion of hepatitis-B exposed babies that had the birth dose of hepatitis B vaccine within 24hours, the proportion of babies that completed the 3doses of the hepatitis B vaccine at the appropriate time, spontaneous miscarriage rate, preterm delivery rate, mean birthweight and the perinatal mortality rate of the hepatitis B-exposed infants.

Results

A total of 10,866 eligible pregnant women were screened during the study period, of which 395 tested positive to the HBsAg, giving a prevalence of 3.64%. The mean age of the women was 31.51 ± 5.71 years, with a median parity of 1.2. More than half (53.9%) were screened before the 28th week of pregnancy, and 249 women (63%) had the complete hepatitis B viral assay done. The remaining expectant mothers (146:37%) could not do the complete hepatitis B serological markers due to financial constraints. All the HBsAg positive women had chronic hepatitis B infection. In addition, 13 (5.2%) of the 249 HBsAg positive women expressed HBeAg in their serum, while 162 women (65.1%) had developed the anti-HBe antibody. Three patients had both the HBeAg and the HBeAb contemporaneously. Only 21 patients had HBV DNA assay done, with values that ranged between 20IU/ml and 7,456IU/ml. Consequently, none of them attained the viral load trigger for prenatal TDF. Of the 486 pre-existing hepatitis-B exposed children before the index pregnancy, 225 (46.3%), with ages ranging between 2years and 22years were tested and seven (3.1%) were HBsAg positive. The other children were not tested because their parents did not give consent. Seventeen women had prenatal TDF administered from 28weeks gestation till delivery. Eight (2.0%) of the 395 women with chronic HBV infection had HBV-HIV co-infection.

1
2
3 Of the 395 women with positive HBsAg, there was one spontaneous miscarriage, while 18 patients
4 were lost to follow-up (see figure 1). Further analysis was therefore based on 376 women that
5 completed the study with known perinatal outcomes. With respect to mode of delivery, 219 women
6 (58.2%) had spontaneous vaginal delivery, with a Caesarean section rate of 41.8%. The mean birth
7 weight of the babies was 3.21 ± 1.86 kg. Forty women (10.2%) had preterm births, defined as
8 spontaneous or provider-initiated delivery for obstetric reasons, before 37 completed weeks, and
9 there were 11 perinatal mortalities (comprising six stillbirths and five early neonatal deaths), with
10 a stillbirth rate of 15.9/1,000 births and a perinatal mortality rate of 29.2/1,000 births. The details
11 of the perinatal mortalities are depicted on table 1. One of the 17 women that had prenatal TDF
12 had a stillbirth from complications of obstructed labour outside the facility; there was no other
13 complication recorded among the remaining 16 women. All the babies were breastfed (Figure 1).

14
15
16
17
18
19
20
21
22
23 The birth dose of hepatitis B vaccine was administered to all the 365 newborns; 327 babies (89.6%)
24 had the vaccine administered within 24 hours of delivery, while the remaining 38 babies (10.4%)
25 had delayed vaccination within 2-4 days postpartum due to logistic reasons. There was a diarrhea-
26 related infant mortality among the cohort, leaving 364 babies (99.7%) that completed the
27 vaccination at the appropriate time. In addition, 260 (71.3%) babies had both hepatitis B vaccine
28 and the Hepatitis B immunoglobulin combination; the remaining 105 babies (28.7%) did not have
29 the HBIG administered due to financial constraints. Only eight (61.5%) of the 13 women with
30 HBeAg had the hepatitis B vaccine-HBIG combination administered to their babies. The entire
31 hepatitis-B exposed cohort of 364 children tested HbsAg negative at the exit-hepatitis B screening
32 that was conducted at 9 between 9-10 months postnatally.

33 34 35 36 37 38 39 40 41 **Discussion**

42
43 In 2020, the WHO Interim guidance for country validation of viral hepatitis elimination was
44 launched, with absolute targets that include HBsAg prevalence $\leq 0.1\%$ in those aged 5 years or
45 less, 95% reduction in mother to child transmission rates and an absolute hepatitis B related annual
46 mortality rate of <4 per 100,000 persons. To achieve this, each country is expected to target at least
47 90% coverage of maternal antenatal HBsAg testing, $\geq 90\%$ coverage with antivirals for those
48 eligible, 90% timely administration of the birth dose of hepatitis B vaccine, and $\geq 90\%$ of 3 doses
49 (HepB3) vaccine coverage¹. This vaccination is expected to confer immunity on at least 95% of
50 the vaccinated infants. Co-administration of hepatitis B immunoglobulin (HBIG) may also be used
51
52
53
54
55
56
57
58
59
60

1
2
3 to further reduce the risk of MTCT of HBV. This study met all the set targets, with absolute
4 prevention of vertical and early childhood transmission of hepatitis B virus up to the age of 9
5 months among the cohort. This conforms to the findings of some studies that had earlier reported
6 0% transmission rate following initiation of immunoprophylaxis within 24 hours of birth^{11,12}.
7
8 Meanwhile, seven (3.1%) of the 225 already existing children that were delivered to the same
9 cohort of women before the commencement of this protocol were HBsAg positive. This further
10 underpins the immense role of the hepatitis B preventative measures at eliminating vertical
11 transmission.
12
13
14
15
16

17 Expression of HBeAg significantly heightens the risk of vertical transmission of HBV. In a
18 systematic review of 15 articles from 11 African countries including Nigeria by Keane et al, the
19 pooled risks of vertical transmission of hepatitis B virus among 34 HBeAg positive mothers was
20 38.3% (95% CI: 7.0–74.4%) without prophylaxis, and 4.8% (95% CI: 0.1–13.3%) among HBeAg
21 negative mothers, without prophylaxis. These rates are similar to the 40% and 5% transmission
22 rates for HBeAg-positive and -negative mothers respectively, by WHO (3) This risk was however
23 eliminated among the 13 HBeAg positive women in the index study due to the combination of
24 prenatal TDF from the 28th week of gestation and postpartum prophylaxis in the exposed children.
25 This approach has been proven to be more effective among HBeAg positive mothers than
26 vaccination at birth alone, at preventing vertical transmission^{3,13}. Prenatal TDF is already supplied
27 to HIV positive patients at no cost. Such privilege is, however, not yet available to HBV positive
28 women^{11,14}. It is advisable that the country leverages on the supply chain that is already available
29 for HIV PMTCT programmes, for the prevention of HBV as well.
30
31
32
33
34
35
36
37
38
39

40 Almost 30% of the children in this study did not have the HBIG administered due to financial
41 constraints. This is not unexpected, as such medications are expensive and only available on an
42 “out-of-pocket” payment basis, and according to the World Bank and the National Bureau of
43 Statistics (NBS) of Nigeria, about 40% of Nigeria’s population, amounting to about 83 million
44 people, live below the country’s poverty line of \$381.75 per annum¹⁵. There was, however, no
45 difference in the outcome of the children in the hepatitis B vaccine-HBIG combination and the
46 hepatitis B vaccine alone groups. This observation aligns with an earlier report that the efficacy of
47 appropriately administered hepatitis B vaccine is comparable to that of hepatitis B vaccine-HBIG
48 combination¹⁶, and the WHO recommendation of HepB3 as the primary preventative measure for
49 hepatitis B-exposed children, with expected immunity rate of 95%. This finding is of significant
50
51
52
53
54
55
56
57
58
59
60

1
2
3 relevance, especially in low- and middle-income countries such as Nigeria, where a dose (200iu)
4 of HBIG as at the time of the study costs about 70,000 Nigerian Naira, equivalent to 166 US
5 Dollars. Meanwhile, the hepatitis B vaccine is available at no cost to all newborns as a national
6 policy through governmental efforts in Nigeria. The use of hepatitis B vaccine is recorded to have
7 prevented 210million new chronic infections so far, and over a million deaths will be averted
8 within the next 8 years. It is therefore essential that health care facilities and systems in LMICs,
9 including Nigeria prioritize achievement of the set targets for hepatitis B vaccination, to maximize
10 the benefits from the already existing governmental policies. Without doing this, however, about
11 63 million new chronic infections and 17million deaths could be recorded within the same period¹⁷.
12 With respect to obstetric outcomes, the prematurity rate is comparable with the report for the
13 general obstetric population. The Caesarean section rate was comparable to the 47% reported from
14 an earlier study, and the mean birthweight was also comparable to the 3210 ± 490g reported by
15 Awowole et al from the same center 3 years earlier¹⁸. Hepatitis B infection in pregnancy was not
16 associated with increased stillbirth or perinatal mortality rate among the cohort in this study, as the
17 findings were comparable to the stillbirth rate of 15/1,000 births recorded by Kuti et al among
18 unselected booked patients at the same facility¹⁹. The perinatal mortality rate of 29.2/1,000 births
19 from this study, though high, is comparable to the perinatal mortality rate of 38/1,000 births
20 reported by the Nigerian Demographic and Health Survey for the southwest geopolitical zone,
21 where the OAUTHC is situated⁷. Chronic asymptomatic hepatitis B infection in pregnancy was
22 therefore not associated with increased Caesarean section, low birth weight, stillbirth, and perinatal
23 mortality rates in this study.

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40 The mother-to-child-transmission of hepatitis B infection rate of 0% at 9 months in this study is
41 comparable to the findings from some earlier studies that reported similar transmission rates,
42 following initiation of the birth dose of the hepatitis B vaccine within 24hours of delivery^{11,12,14}.
43 Meanwhile, seven (3.1%) of the 225 children delivered to the same cohort of women before the
44 commencement of this protocol were HBsAg positive. This further underpins the immense role of
45 the hepatitis B preventative measures at eliminating vertical transmission.

46
47
48
49
50
51 One of the strengths of this study is the sample size, which involves the largest cohort of hepatitis
52 B virus positive pregnant women to be prospectively recruited and actively managed in Nigeria,
53 translating to generation of reliable and credible data. The multidisciplinary nature of the study,
54
55
56
57
58
59

1
2
3 with involvement of Specialists from Obstetrics, Gastroenterology, Paediatrics and Child Health,
4 Public Health, the Childhood Immunization Sub-unit and the Community Health Extension
5 Workers made in-facility and community monitoring, surveillance, and painstaking
6 implementation of the hepatitis B EMTCT interventions feasible in the study cohort. This research
7 is also the only study in Nigeria, to prospectively follow up and report the outcomes of hepatitis B
8 exposed children till the age of 9 months, following implementation of HBV EMTCT measures. In
9 addition, this is the first study from Nigeria that endeavored to screen all the pre-existing children
10 of consenting hepatitis B pregnant women, with appropriate follow-up at the Paediatric and Child
11 Health Unit of the Teaching Hospital, thereby utilising the antenatal period as a window of
12 opportunity to provide a family-centered, holistic care to the affected women.
13
14
15
16
17
18
19
20

21 This study also has some identifiable limitations. Since 2020, WHO has updated its
22 recommendation to include the administration of TDF to pregnant women with HBV DNA
23 $\geq 200\ 000$ IU/mL to prevent mother-to-child transmission (PMTCT) of HBV^{1,20}. One of the
24 limitations of this study is however the inability to undertake the quantitative HBV DNA in all the
25 women due to financial constraints. This, however, did not significantly affect the outcome of the
26 study. Secondly, the additional benefit of HBIG among HBV-positive women in low-resource
27 settings could have been better assessed using a randomized controlled trial, as this study was not
28 designed to specifically detect the comparative effectiveness of Hepatitis B vaccine alone versus
29 hepatitis B vaccine-HBIG combination therapy. Withholding HBIG from the control group,
30 especially for patients that could afford it would however have been unethical. Nevertheless,
31 further trials to appraise this observation will be needed in the future. It is also not clear whether
32 the pre-existing children that tested positive to the hepatitis B virus acquired the infections
33 vertically at birth or horizontally in early childhood. Discerning this may however not be
34 significant, as the endpoint of chronic childhood hepatitis B infection are similar. Furthermore, the
35 vaccination status of the pre-existing children could not be evaluated with certainty. Lastly,
36 screening for anti-HBs titre has been recommended for HBsAg-negative infants as anti-HBs levels
37 ≥ 100 mIU/ml are considered protective with no need for further medical management²¹. Screening
38 for anti-HBs was not done in this study for the 364 babies that were HBsAg-negative at 9 months
39 of age due to financial constraints.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 In conclusion, this study demonstrates that achieving the set goals for eliminating mother-to-child
4 transmission of hepatitis B infection is feasible, even in the absence of high-end investigations
5 such as HBV DNA assay, and expensive interventions such as the HBIG, especially in LMICs
6 with the highest burden of chronic HBV infections and limited resources. Chronic hepatitis B
7 infection did not demonstrate adverse effect on the outcome of the pregnancies. A national scale-
8 up of these interventions in Nigeria through committed vaccination policies, sustained
9 governmental funding and commitment, as well as universal health coverage are required to bridge
10 the gap for the patients that live below poverty line in Nigeria and would therefore not be able to
11 afford even the most basic of these interventions.
12
13
14
15
16
17
18

19 **Author Contributions:** DN and OK conceived the study. DN, OK, IA, OA, OI, OM, AA, CA and
20 MI all participated in participated in literature search, proposal writing, study design, supervision
21 of sample collection, patient management, critical review of the manuscript for intellectual content,
22 and approval of the final draft and agree to take responsibility for the integrity of the research.
23
24
25
26

27 **Data sharing statement:** Data are available upon reasonable request.
28

29 **Funding:** This research received no specific grant from any funding agency in the public,
30 commercial or not-for-profit sectors.
31
32

33 **Competing interests:** All the authors hereby declare no competing interests.
34
35

36 **Acknowledgements:** The research team wishes to acknowledge the immense contributions of
37 Matron Lawal G.O, Mrs Morakinyo, Mrs Omiwole O. and Miss Olaiwon S. to the successful
38 completion of this research.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. World Health Organization. Interim guidance for country validation of viral hepatitis elimination. Geneva: World Health Organization; 2021.
2. World Health Organization. Regional Action Plan for Viral Hepatitis in the Western Pacific 2016–2020. Geneva: World Health Organization; 2016.
3. World Health Organization. Global Hepatitis Report, 2017. Geneva: World Health Organization; 2017.
4. Center for Disease Control. Global Viral Hepatitis: Millions of People are Affected. 2021: Available at <https://www.cdc.gov/hepatitis/global/index.htm>.
5. Federal Ministry of Health Nigeria. National Guidelines for the Prevention, Treatment and Care of Viral Hepatitis in Nigeria. FMOH; Abuja: Nigeria; 2016.
6. Breakwell L, Tevi-Benissan C, Childs L, Mihigo R, Tohme R. The status of hepatitis B control in the African region. *Pan Afri Med J.* 2017;27:17.
7. National Population Commission (NPC) [Nigeria] and ICF. Nigeria DHS Key Findings. Abuja, Nigeria and Rockville, Maryland, USA: National Population Commission; 2019.
8. World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2021: Towards Ending Viral Hepatitis. Geneva: World Health Organization; 2016.
9. Mbaawuaga EM, Enenebeaku MNO, Okopi JA, Damen JG. Hepatitis B Virus (HBV) Infection among Pregnant Women in Makurdi, Nigeria. *Afri J Biomed Res.* 2008;11:155-9.
10. BT Utoo. Hepatitis B surface antigenemia (HBsAg) among pregnant women in southern Nigeria. *Afri Health Sci.* 2013;13(4):1139-43.
11. Onakewhor JUE, Charurat M, Matthew O, Osagie E, Asemota MO, Omoigberale A. Serologic Pattern of Hepatitis B Infection among Exposed and Non-Exposed Babies in A PMTCT Program in Low Resource Setting: Does Every Exposed Newborn Require 200IU of Hepatitis B Immunoglobulin? *J Vaccines Vaccin.* 2013;4:7.
12. Keane E, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. *Aliment Pharmacol Ther.* 2016;44:1005-17.

13. Brown RS Jr, McMahon BJ, Lok ASF, Wong JB, Ahmed AT, Mouchli MA, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. *Hepatology*. 2016;63(1):319-33.
14. Ekraa D, Herbingerb K, Konatec S, Leblond A, Fretz C, Ciloteb V, et al. A non-randomized vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first dose at birth or age 6 weeks in Côte d'Ivoire. *Vaccine*. 2008;26 (22):2753-61.
15. The World Bank. Nigeria releases new report on poverty and inequality in country: 2021. Available at <https://www.worldbank.org/en/programs/lms/brief/nigeria-releases-new-report-on-poverty-and-inequality-in-country>.
16. Lolekha S, Warachit B, Hirunyachote A, Bowonkiratikachorn P, West DJ, Poerschke G. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand. *Vaccine*. 2002:3739–43.
17. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for global elimination of hepatitis B: a modelling study. *Lancet Infect Dis* 2016;16:1399–408.
18. Awowole IO, Kuti O, Asaleye CM, Badejoko OO, Bola-Oyebamiji SB, Olatunji RB, et al. Normative References and Clinical Correlates of Fetal Umbilical Artery Doppler Indices in Southwestern Nigeria. *Int J Gynaecol Obstet*. 2020;151:134-40.
19. Kuti O, Awowole IO, Okunola TO. Audit of stillbirths in a Nigerian teaching hospital. *Trop J Obstet Gynaecol*. 2017;34(3):188-94.
20. World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization; 2020.
21. Hou J, Cui F, Ding Y, Dou X, Duan Z, Han G et al. Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. *Clinical Gastroenterology and Hepatology*, 2019; 17: 1929 – 1936.

Figure Legend

Figure 1: Algorithm for HBsAg screening of pregnant women and hepatitis B birth dose vaccination of exposed babies.

Table 1: Causes of perinatal deaths among women with hepatitis B infection in pregnancy at OAUTHC.

Cause	Perinatal mortality N = 11		Total
	Stillbirths	Neonatal Deaths	Frequency (%)
Antepartum haemorrhage	2	1	3 (27.3)
Eclampsia	1	1	2 (18.2)
Obstructed labour*	1	1	2 (18.2)
Out-of-facility delivery	0	2	2 (18.2)
Fetal Growth Restriction	1	0	1 (9.1)
Unexplained	1	0	1 (9.1)
Total	6	5	11(100)

*Patients presented late to the facility after initial management at unorthodox centers.




Figure 1: Algorithm for HBsAg screening of pregnant women and hepatitis B birth dose vaccination of exposed babies

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	4
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	6
		(d) If applicable, explain how loss to follow-up was addressed	7
		(e) Describe any sensitivity analyses	NA
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	Yes
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6
		(b) Indicate number of participants with missing data for each variable of interest	6
		(c) Summarise follow-up time (eg, average and total amount)	6
Outcome data	15*	Report numbers of outcome events or summary measures over time	6
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	6
Discussion			
Key results	18	Summarise key results with reference to study objectives	7
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	7
Generalisability	21	Discuss the generalisability (external validity) of the study results	8
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	10

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Prospective Cohort Study of Prevention of Mother to Child Transmission of Hepatitis B Infection and Nine Months Follow-up of Hepatitis B-exposed Infants at Ile-Ife, Nigeria.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-063482.R2
Article Type:	Original research
Date Submitted by the Author:	17-Oct-2022
Complete List of Authors:	Ndububa, Dennis; Obafemi Awolowo University, Department of Medicine Kuti, Oluwafemi; Obafemi Awolowo University, Department of Obstetrics, Gynaecology and Perinatology Awowole, Ibraheem; Obafemi Awolowo University, Obstetrics, Gynaecology and Perinatology; Obafemi Awolowo University Teaching Hospital Complex, Obstetrics, Gynaecology and Perinatology Adekanle, Olusegun; Obafemi Awolowo University, Department of Medicine Ijarotimi, Oluwasegun; Obafemi Awolowo University, Department of Medicine Makinde, Olufemiwa; Obafemi Awolowo University, Department of Obstetrics, Gynaecology and Perinatology Adeyemi, Adebajo B; Obafemi Awolowo University, Department of Obstetrics, Gynaecology and Perinatology Anyabolu, Chineme; Obafemi Awolowo University, Department of Paediatrics and Child Health Ijadunola, Macellina; Obafemi Awolowo University, Department of Community Health
Primary Subject Heading:	Obstetrics and gynaecology
Secondary Subject Heading:	Gastroenterology and hepatology
Keywords:	Adult gastroenterology < GASTROENTEROLOGY, Fetal medicine < OBSTETRICS, Maternal medicine < OBSTETRICS, Hepatobiliary disease < GASTROENTEROLOGY, PERINATOLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Prospective Cohort Study of Prevention of Mother to Child Transmission of Hepatitis B**
4 **Infection and Nine Months Follow-up of Hepatitis B-exposed Infants at Ile-Ife, Nigeria.**
5
6

7 Dennis Ndububa; Department of Medicine, Obafemi Awolowo University, Ile-Ife, Osun State,
8 Nigeria. dennisandububa@yahoo.co.uk.
9

10
11 Oluwafemi Kuti: Department of Obstetrics, Gynaecology and Perinatology, Obafemi Awolowo
12 University, Ile-Ife, Osun State, Nigeria. okuti_victory@yahoo.com
13

14
15 Ibraheem Awowole: Department of Obstetrics, Gynaecology and Perinatology, Obafemi
16 Awolowo University, Ile-Ife, Osun State, Nigeria. iawowole@oauife.edu.ng
17

18
19 Olusegun Adekanle: Department of Medicine, Obafemi Awolowo University, Ile-Ife, Osun State,
20 Nigeria. olusegunadekanle@oauife.edu.ng
21

22
23 Oluwasegun Ijarotimi: Department of Medicine, Obafemi Awolowo University, Ile-Ife, Osun
24 State, Nigeria. segjarot@hotmail.com
25

26
27 Olufemiwa Makinde: Department of Obstetrics, Gynaecology and Perinatology, Obafemi
28 Awolowo University, Ile-Ife, Osun State, Nigeria. niyimakinde20022003@yahoo.com.
29

30
31 Adebajo Adeyemi: Department of Obstetrics, Gynaecology and Perinatology, Obafemi Awolowo
32 University, Ile-Ife, Osun State, Nigeria. babloola@yahoo.com
33

34
35 Chineme Anyabolu: Department of Paediatrics and Child Health, Obafemi Awolowo University,
36 Ile-Ife, Osun State, Nigeria.
37

38
39 Macellina Ijadunola: Department of Community Health, Obafemi Awolowo University, Ile-Ife,
40 Osun State, Nigeria. yijadun@oauife.edu.ng
41

42
43
44 **Corresponding Author:**
45

46 Ibraheem O. Awowole (FWACS, MRCOG)

47
48 Perinatology Unit, Department of Obstetrics, Gynaecology and Perinatology,
49

50
51 Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria.220005.
52

53
54 +2348033767719, iawowole@oauife.edu.ng
55

Abstract

Objectives: Eliminating Mother-to-Child-Transmission (MTCT) of Hepatitis B Virus (HBV) is central to WHO's target of reducing hepatitis B infection in children to <0.1% by 2030. While Nigeria accounts for 8.3% of the global burden, interventional studies on prevention of MTCT of HBV are hardly available. This study aimed to assess the impact of prevention of MTCT interventions on vertical transmission of HBV among pregnant women in Nigeria.

Design: A prospective cohort study

Setting: A University Teaching Hospitals Complex in Nigeria between 2015-2021.

Participants: 10,866 pregnant women and their pre-existing children.

Interventions: Eligible pregnant women were screened for HBsAg using chromatographic immunoassay (Micropoint®, USA). HbsAg-positive women had HBV serological assay done and their pre-existing children were screened. Women with HBV DNA $\geq 200,000$ IU/ml and those positive for HBeAg had 300mg daily of Tenofovir Disoproxil Fumarate (TDF) in the 3rd trimester. The newborns had hepatitis B vaccines and HB Immunoglobulin (HBIG) administered, followed by testing for HBsAg at 9 months post-natally.

Primary outcome measures: Prevalence of chronic hepatitis B infection in pregnancy, and the incidence of MTCT of HBV.

Results: Overall, 395 women had chronic HBV infection, giving a prevalence of 3.64%. Their mean age was 31.51 ± 5.71 years, with a median parity of 1.2. Thirteen women (5.2%) were positive for HBeAg, seven (3.1%) of the 225 pre-existing hepatitis B-exposed children were HbsAg positive, and 17 women had prenatal TDF. Overall, 376 women completed the study, with mean birthweight of 3.21 ± 1.86 kg and perinatal mortality rate of 29.2/1,000 births. Hepatitis B vaccine-HBIG combination was administered to 260 newborns, while the others had hepatitis B vaccine alone. All the children tested negative to the HbsAg at 9 months.

Conclusion: Eliminating MTCT of hepatitis B virus infection through validated protocols in Low- and Middle-Income Countries (LMICs) with the highest burden of chronic HBV infections is feasible. National scale-up of such protocols is recommended.

Article Summary

Strengths and limitations of this study

- This study involves the largest cohort of hepatitis B pregnant women to be prospectively recruited and actively managed in Nigeria.
- The multidisciplinary nature of the study of the managing team made implementation of the hepatitis B EMTCT interventions feasible.
- This research is the only study to actively intervene, prospectively follow up and report the outcomes of hepatitis B exposed children till the age of 9 months in Nigeria.
- HBV DNA assay could not be routinely done in the HBsAg-positive women due to financial constraints.

Keywords: Chronic hepatitis B, Hepatitis B virus, Hepatitis B vaccine, Hepatitis B immunoglobulin, Mother-to-child transmission, Nigeria

Word count: 2,974

Introduction

The World Health Organization (WHO) estimates that 1.4 million deaths are recorded annually due to viral hepatitis, and hepatitis-associated mortality now ranks as the 7th leading cause of death globally, ahead of deaths due to HIV/AIDS, Malaria and Tuberculosis. This burden is mainly associated with Hepatitis B virus (48%) and Hepatitis C virus (48%)¹. Overall, about 2 billion people are estimated to have evidence of past or present hepatitis B infection, with Africa and the Western Pacific regions alone accounting for 67% of the global burden. Mother-to-child-transmission of Hepatitis B Virus (HBV) is a major route of transmitting the infection in low-and middle-income countries (LMIC), due to its propensity to progress into chronicity¹⁻³.

The Center for Disease Control (CDC) estimated the prevalence of chronic hepatitis B infection in Nigeria to be at least 8%⁴. This was confirmed by the recent report from the Federal Ministry of Health, making Nigeria the country with the highest burden globally⁵. Despite the high burden, most hospitals in Nigeria and other developing countries have no protocol in place to address the

1
2
3 problem. In 2018, only 52.4% of Nigerian children reportedly received the birth dose of hepatitis
4 B vaccine while only 50.3% completed the three additional doses of the vaccine⁶. To achieve the
5 Global Health Sector Strategy (GHSS) on viral hepatitis, the WHO has set the target of reducing
6 HBsAg prevalence in children to 0.1% by 2030⁷. Appropriately designed prospective studies to
7 generate relevant data are imperative to achieve this goal.
8
9

10
11
12 Although some Nigerian researchers have evaluated the outcomes of pregnancies among women
13 with hepatitis B virus infection, many of these studies were either retrospectively conducted or
14 simply prevalence studies that did not control for or report the quality of prevention of mother to
15 child transmission of hepatitis B care that the study subjects received^{8,9}; none had therefore
16 reported on the outcome of implementing a well designed and implemented protocol. While
17 Onakewhor et al reported the administration of hepatitis B vaccine and HBIG immunoprophylaxis
18 for PMTCT among a Nigerian cohort, the study had a sample size of only 45 patients¹⁰. This study
19 was therefore designed to meticulously implement the EMTCT of hepatitis B measures, and to
20 follow the hepatitis B-exposed babies till the age of 9 months, for the purpose of identifying
21 perinatal vertical and early childhood horizontal transmissions.
22
23
24
25
26
27
28
29

30 **Methods**

31
32
33 **Study setting:** The study was undertaken at the Perinatal Unit of the Department of Obstetrics,
34 Gynaecology and Perinatology, and the Gastroenterology Unit of the Department of Medicine,
35 Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun State, Nigeria between
36 November 2015, and March 2021.
37
38
39

40
41 **Design:** The study is a prospective cohort study.
42

43 **Study participants:** All consecutive pregnant women that booked for antenatal care at the
44 institution were prospectively recruited for the study after appropriate counseling. As the study
45 was descriptive without any hypothesis testing, a specific sample size wasn't calculated.
46
47
48

49 **Inclusion criteria:** All pregnant women that received antenatal care at the Obafemi Awolowo
50 University Teaching Hospitals Complex, Ife, Osun State, Nigeria during the study period.
51
52

53 **Exclusion criteria:** Pregnant women that refused to consent to HBV screening.
54
55
56
57
58
59
60

1
2
3 **Statistical analysis:** the data was analysed with IBM SPSS 20.0. Categorical variables were
4 presented in frequencies and percentages while continuous variables were presented as means and
5 standard deviations.
6
7

8
9 **Patient and public involvement:** It was not possible to involve patients in the design and conduct
10 of the study, but they will be involved in the dissemination of the study findings, for ease of
11 widespread dissemination.
12
13

14
15 **Ethics Approval:** Research approval for the study was obtained from the Obafemi Awolowo
16 University Teaching Hospitals Complex Ethics and Research Board (IRB/IEC/0004553:
17 ERC/20/02/010).
18
19

20
21 **Intervention:** After obtaining informed consent from each study participant, relevant data
22 regarding the socio-demographic characteristics of the women were captured using a purpose-
23 designed proforma. Provider-initiated counselling and testing of the participants' serum for
24 HBsAg was undertaken for all consecutive pregnant women by the Nurses at the antenatal clinic,
25 using chromatographic immunoassay (Micropoint®, USA) rapid diagnostic kit. In addition to
26 HBsAg testing, all the women also had retroviral screening done after due counselling. HBsAg
27 positive women subsequently had the complete hepatitis B serological markers assay done,
28 comprising the Hepatitis B surface Antibody (HBsAb), Hepatitis B core antibody (HBcAb: Total
29 and IgG). Hepatitis B e-antigen (HBeAg) and the Hepatitis B e-antibody (HBeAb), using
30 Micropoint® kit, for the purpose of categorization and prognostication. To ensure compliance,
31 95% subsidy on the cost of the hepatitis B serological marker was provided by the research team.
32 HBV DNA assay was also routinely requested for all the HBsAg positive patients, but this was not
33 subsidised. Chronic Hepatitis B (CHB) infection was defined as the presence of HBsAg for more
34 than 6 months in the participants, or the presence of the IgG fraction of the Hepatitis B core
35 antibody, with absent HBsAb and IgM fraction. All the pregnant women diagnosed with CHB
36 were encouraged to bring their pre-existing children for testing and those identified as HBsAg
37 positive were referred for necessary treatment at the Paediatric and Child Health Department of
38 the hospital. Three categories of women were considered for antenatal treatment with Tenofovir
39 Disoproxil Fumarate (TDF), namely, those with serum HBV DNA $\geq 200,000$ IU/ml, women
40 positive for HBeAg without serum HBeAb, and women with history of perinatal transmission in
41 their previous pregnancies. Pregnant women in any of these categories were placed on TDF 300mg
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 orally once daily starting from the 28th week of gestation till delivery, or as soon as possible, if the
4 diagnosis was made after the 28th week of gestation. Adherence to medication was assessed during
5 outpatient follow-up by the Gastroenterologists, who were also members of the research team. The
6 mode of delivery was determined strictly by obstetric indications. Serial phone calls were placed
7 to all the study participants by dedicated research staff and community health workers as their
8 pregnancies advanced, to ensure compliance with antenatal care and postpartum EMTCT of
9 hepatitis B advisories. Those who delivered out-of-facility were therefore identified and necessary
10 EMTCT of hepatitis B measures were implemented without delay. All the babies that were
11 delivered within the study period, irrespective of the place of birth or the day of the week, had the
12 birth dose of the hepatitis B vaccine administered within 24 hours of delivery by the National
13 Programme on Immunization (NPI) department. When affordable to the patient, 200iu of the
14 Hepatitis B Immunoglobulin (HBIG) was also administered to the newborns of the hepatitis B
15 positive parturients within 24 hours of delivery, while the mothers were referred to the
16 Gastroenterology Unit for continuity of care. All the babies were followed up on phone to ensure
17 strict compliance with the national vaccination schedule, including the hepatitis B vaccination.
18 The infants were tested at the age of 9 months, to assess their hepatitis B infection status. The
19 primary outcome measure was the proportion of infants that tested positive to the HBsAg at the
20 age of 9 months. Secondary outcomes were the proportion of hepatitis-B exposed babies that had
21 the birth dose of hepatitis B vaccine within 24hours, the proportion of babies that completed the
22 3doses of the hepatitis B vaccine at the appropriate time, spontaneous miscarriage rate, preterm
23 delivery rate, mean birthweight and the perinatal mortality rate of the hepatitis B-exposed infants.

40 **Results**

41
42 A total of 10,866 eligible pregnant women were screened during the study period, of which 395
43 tested positive to the HBsAg, giving a prevalence of 3.64%. The mean age of the women was
44 31.51± 5.71years, with a median parity of 1.2. More than half (53.9%) were screened before the
45 28th week of pregnancy, and 249 women (63%) had the complete hepatitis B viral assay done. The
46 remaining expectant mothers (146:37%) could not do the complete hepatitis B serological markers
47 due to financial constraints. All the HBsAg positive women had chronic hepatitis B infection. In
48 addition, 13 (5.2%) of the 249 HBsAg positive women expressed HBeAg in their serum, while
49 162 women (65.1%) had developed the anti-HBe antibody. Three patients had both the HBeAg
50
51
52
53
54
55
56
57
58
59
60

1
2
3 and the HBeAb contemporaneously. Only 21 patients had HBV DNA assay done, with values that
4 ranged between 20IU/ml and 7,456IU/ml. Consequently, none of them attained the viral load
5 trigger for prenatal TDF. Of the 486 pre-existing hepatitis-B exposed children before the index
6 pregnancy, 225 (46.3%), with ages ranging between 2years and 22years were tested and seven
7 (3.1%) were HBsAg positive. The other children were not tested because their parents did not give
8 consent. Seventeen women had prenatal TDF administered from 28weeks gestation till delivery.
9 Eight (2.0%) of the 395 women with chronic HBV infection had HBV-HIV co-infection.

10
11
12 Of the 395 women with positive HBsAg, there was one spontaneous miscarriage, while 18 patients
13 were lost to follow-up (see figure 1). Further analysis was therefore based on 376 women that
14 completed the study with known perinatal outcomes. With respect to mode of delivery, 219 women
15 (58.2%) had spontaneous vaginal delivery, with a Caesarean section rate of 41.8%. The mean birth
16 weight of the babies was 3.21 ± 1.86 kg. Forty women (10.2%) had preterm births, defined as
17 spontaneous or provider-initiated delivery for obstetric reasons, before 37completed weeks, and
18 there were 11 perinatal mortalities (comprising six stillbirths and five early neonatal deaths), with
19 a stillbirth rate of 15.9/1,000 births and a perinatal mortality rate of 29.2/1,000 births. The details
20 of the perinatal mortalities are depicted on table 1. One of the 17 women that had prenatal TDF
21 had a stillbirth from complications of obstructed labour outside the facility; there was no other
22 complication recorded among the remaining 16 women. All the babies were breastfed (Figure 1).

23
24
25 The birth dose of hepatitis B vaccine was administered to all the 365 newborns; 327 babies (89.6%)
26 had the vaccine administered within 24hours of delivery, while the remaining 38 babies (10.4%)
27 had delayed vaccination within 2-4 days postpartum due to logistic reasons. There was a diarrhea-
28 related infant mortality among the cohort, leaving 364 babies (99.7%) that completed the
29 vaccination at the appropriate time. In addition, 260 (71.3%) babies had both hepatitis B vaccine
30 and the Hepatitis B immunoglobulin combination; the remaining 105 babies (28.7%) did not have
31 the HBIG administered due to financial constraints. Only eight (61.5%) of the 13 women with
32 HBeAg had the hepatitis B vaccine-HBIG combination administered to their babies. The entire
33 hepatitis-B exposed cohort of 364 children tested HbsAg negative at the exit-hepatitis B screening
34 that was conducted at 9months postnatally.

35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 **Discussion**

1
2
3 This study met all the set targets of the WHO Interim guidance for the elimination of hepatitis B¹,
4 with absolute prevention of vertical and early childhood transmission of hepatitis B virus up to the
5 age of 9 months among the cohort. This conforms to the findings of some studies that had earlier
6 reported 0% transmission rate following initiation of immunoprophylaxis within 24 hours of
7 birth^{9,10}. Meanwhile, seven (3.1%) of the 225 already existing children that were delivered to the
8 same cohort of women before the commencement of this protocol were HBsAg positive.
9

10
11
12
13
14 Expression of HBeAg significantly heightens the risk of vertical transmission of HBV. In a
15 systematic review of 15 articles from 11 African countries including Nigeria by Keane et al¹¹, the
16 pooled risks of vertical transmission of hepatitis B virus among 34 HBeAg positive mothers was
17 38.3% (95% CI: 7.0–74.4%) without prophylaxis, and 4.8% (95% CI: 0.1–13.3%) among HBeAg
18 negative mothers, without prophylaxis. These rates are similar to the 40% and 5% transmission
19 rates for HBeAg-positive and -negative mothers respectively, by WHO³. This risk was however
20 eliminated among the 13 HBeAg positive women in the index study due to the combination of
21 prenatal TDF from the 28th week of gestation and postpartum prophylaxis in the exposed children.
22 This approach has been proven to be more effective among HBeAg positive mothers than
23 vaccination at birth alone, at preventing vertical transmission^{3,12}. Prenatal TDF is already supplied
24 to HIV positive patients at no cost. Such privilege is, however, not yet available to HBV positive
25 women^{10,13}. It is advisable that the country leverages on the supply chain that is already available
26 for HIV PMTCT programmes, for the prevention of HBV as well.
27

28
29
30
31
32
33
34
35
36
37 Almost 30% of the children in this study did not have the HBIG administered due to financial
38 constraints. This is not unexpected, as such medications are expensive and only available on an
39 “out-of-pocket” payment basis. There was, however, no difference in the outcome of the children
40 in the hepatitis B vaccine-HBIG combination and the hepatitis B vaccine alone groups. This
41 observation aligns with an earlier report that the efficacy of appropriately administered hepatitis B
42 vaccine is comparable to that of hepatitis B vaccine-HBIG combination¹⁴, and the WHO
43 recommendation of HepB3 as the primary preventative measure for hepatitis B-exposed children,
44 with expected immunity rate of 95%. This finding is of significant relevance, especially in low-
45 and middle-income countries such as Nigeria, where a dose (200iu) of HBIG as at the time of the
46 study costs about 70,000 Nigerian Naira, equivalent to 166 US Dollars. Meanwhile, the hepatitis
47 B vaccine is available at no cost to all newborns as a national policy through governmental efforts
48 in Nigeria.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 With respect to obstetric outcomes, the prematurity rate is comparable with the report for the
4 general obstetric population. The Caesarean section rate was comparable to the 47% reported from
5 an earlier study, and the mean birthweight was also comparable to the $3210 \pm 490\text{g}$ reported by
6 Awowole et al from the same center 3 years earlier¹⁵. Hepatitis B infection in pregnancy was not
7 associated with increased stillbirth or perinatal mortality rate among the cohort in this study, as the
8 findings were comparable to the stillbirth rate of 15/1,000 births recorded by Kuti et al among
9 unselected booked patients at the same facility¹⁶. The perinatal mortality rate of 29.2/1,000 births
10 from this study, though high, is comparable to the perinatal mortality rate of 38/1,000 births
11 reported by the Nigerian Demographic and Health Survey for the southwest geopolitical zone,
12 where the OAUTHC is situated⁶. Chronic asymptomatic hepatitis B infection in pregnancy was
13 therefore not associated with increased Caesarean section, low birth weight, stillbirth, and perinatal
14 mortality rates in this study.
15
16

17
18
19 The mother-to-child-transmission of hepatitis B infection rate of 0% at 9 months in this study is
20 comparable to the findings from some earlier studies that reported similar transmission rates,
21 following initiation of the birth dose of the hepatitis B vaccine within 24hours of delivery^{10,11,13}.
22 Meanwhile, seven (3.1%) of the 225 children delivered to the same cohort of women before the
23 commencement of this protocol were HBsAg positive. This further underpins the immense role of
24 the hepatitis B preventative measures at eliminating vertical transmission.
25
26

27
28
29 One of the strengths of this study is the sample size, which involves the largest cohort of hepatitis
30 B virus positive pregnant women to be prospectively recruited and actively managed in Nigeria,
31 translating to generation of reliable and credible data. The multidisciplinary nature of the study,
32 with involvement of Specialists from Obstetrics, Gastroenterology, Paediatrics and Child Health,
33 Public Health, the Childhood Immunization Sub-unit and the Community Health Extension
34 Workers made in-facility and community monitoring, surveillance, and painstaking
35 implementation of the hepatitis B EMTCT interventions feasible in the study cohort. This research
36 is also the only study in Nigeria, to prospectively follow up and report the outcomes of hepatitis B
37 exposed children till the age of 9months, following implementation of HBV EMTCT measures. In
38 addition, this is the first study from Nigeria that endeavored to screen all the pre-existing children
39 of consenting hepatitis B pregnant women, with appropriate follow-up at the Paediatric and Child
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Health Unit of the Teaching Hospital, thereby utilising the antenatal period as a window of
4 opportunity to provide a family-centered, holistic care to the affected women.
5
6

7 This study also has some identifiable limitations. Since 2020, WHO has updated its
8 recommendation to include the administration of TDF to pregnant women with HBV DNA
9 $\geq 200\ 000$ IU/mL to prevent mother-to-child transmission (PMTCT) of HBV^{1,17}. One of the
10 limitations of this study is however the inability to undertake the quantitative HBV DNA in all the
11 women due to financial constraints. This, however, did not significantly affect the outcome of the
12 study. Secondly, the additional benefit of HBIG among HBV-positive women in low-resource
13 settings could have been better assessed using a randomized controlled trial, as this study was not
14 designed to specifically detect the comparative effectiveness of Hepatitis B vaccine alone versus
15 hepatitis B vaccine-HBIG combination therapy. Withholding HBIG from the control group,
16 especially for patients that could afford it would however have been unethical. Nevertheless,
17 further trials to appraise this observation will be needed in the future. It is also not clear whether
18 the pre-existing children that tested positive to the hepatitis B virus acquired the infections
19 vertically at birth or horizontally in early childhood. Discerning this may however not be
20 significant, as the endpoint of chronic childhood hepatitis B infection are similar. Furthermore, the
21 vaccination status of the pre-existing children could not be evaluated with certainty. Lastly,
22 screening for anti-HBs titre has been recommended for HBsAg-negative infants as anti-HBs levels
23 ≥ 100 mIU/ml are considered protective with no need for further medical management¹⁸. Screening
24 for anti-HBs was not done in this study for the 364 babies that were HBsAg-negative at 9 months
25 of age due to financial constraints.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 In conclusion, this study demonstrates that achieving the set goals for eliminating mother-to-child
42 transmission of hepatitis B infection is feasible, even in the absence of high-end investigations
43 such as HBV DNA assay, and expensive interventions such as the HBIG, especially in LMICs
44 with the highest burden of chronic HBV infections and limited resources. Chronic hepatitis B
45 infection did not demonstrate adverse effect on the outcome of the pregnancies. A national scale-
46 up of these interventions in Nigeria through committed vaccination policies, sustained
47 governmental funding and commitment, as well as universal health coverage are required to bridge
48 the gap for the patients that live below poverty line in Nigeria and would therefore not be able to
49 afford even the most basic of these interventions.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Author Contributions:** DN and OK conceived the study. DN, OK, IA, OA, OI, OM, AA, CA and
4 MI all participated in participated in literature search, proposal writing, study design, supervision
5 of sample collection, patient management, critical review of the manuscript for intellectual content,
6 and approval of the final draft and agree to take responsibility for the integrity of the research.
7
8
9

10 **Data sharing statement:** Data are available upon reasonable request.
11
12

13 **Funding:** This research received no specific grant from any funding agency in the public,
14 commercial or not-for-profit sectors.
15
16

17 **Competing interests:** All the authors hereby declare no competing interests.
18
19

20 **Acknowledgements:** The research team wishes to acknowledge the immense contributions of
21 Matron Lawal G.O, Mrs Morakinyo, Mrs Omiwole O. and Miss Olaiwon S. to the successful
22 completion of this research.
23
24

25 **References**

- 26 1. World Health Organization. Interim guidance for country validation of viral hepatitis
27 elimination. Geneva: World Health Organization; 2021.
- 28 2. World Health Organization. Regional Action Plan for Viral Hepatitis in the Western Pacific
29 2016–2020. Geneva: World Health Organization; 2016.
- 30 3. World Health Organization. Global Hepatitis Report, 2017. Geneva: World Health
31 Organization; 2017.
- 32 4. Center for Disease Control. Global Viral Hepatitis: Millions of People are Affected. 2021:
33 Available at <https://www.cdc.gov/hepatitis/global/index.htm>.
- 34 5. Federal Ministry of Health Nigeria. National Guidelines for the Prevention, Treatment and
35 Care of Viral Hepatitis in Nigeria. FMOH; Abuja: Nigeria; 2016.
- 36 6. National Population Commission (NPC) [Nigeria] and ICF. Nigeria DHS Key Findings.
37 Abuja, Nigeria and Rockville, Maryland, USA: National Population Commission; 2019.
- 38 7. World Health Organization. Global Health Sector Strategy on Viral Hepatitis 2016-2021:
39 Towards Ending Viral Hepatitis. Geneva: World Health Organization; 2016.
- 40 8. Mbaawuaga EM, Enenebeaku MNO, Okopi JA, Damen JG. Hepatitis B Virus (HBV)
41 Infection among Pregnant Women in Makurdi, Nigeria. *Afri J Biomed Res.* 2008;11:155-9.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 9. BT Utoo. Hepatitis B surface antigenemia (HBsAg) among pregnant women in southern
4 Nigeria. *Afri Health Sci.* 2013;13(4):1139-43.
- 5
6 10. Onakewhor JUE, Charurat M, Matthew O, Osagie E, Asemota MO, Omoigberale A.
7 Serologic Pattern of Hepatitis B Infection among Exposed and Non-Exposed Babies in A PMTCT
8 Program in Low Resource Setting: Does Every Exposed Newborn Require 200IU of Hepatitis B
9 Immunoglobulin? *J Vaccines Vaccin.* 2013;4:7.
- 10
11 11. Keane E, Funk AL, Shimakawa Y. Systematic review with meta-analysis: the risk of
12 mother-to-child transmission of hepatitis B virus infection in sub-Saharan Africa. *Aliment
13 Pharmacol Ther.* 2016;44:1005-17.
- 14
15 12. Brown RS Jr, McMahan BJ, Lok ASF, Wong JB, Ahmed AT, Mouchli MA, et al. Antiviral
16 therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-
17 analysis. *Hepatology.* 2016;63(1):319-33.
- 18
19 13. Ekraa D, Herbingerb K, Konatec S, Leblond A, Fretz C, Ciloteb V, et al. A non-randomized
20 vaccine effectiveness trial of accelerated infant hepatitis B immunization schedules with a first
21 dose at birth or age 6 weeks in Côte d'Ivoire. *Vaccine.* 2008;26 (22):2753-61.
- 22
23 14. Nayagam S, Thursz M, Sicuri E, Conteh L, Wiktor S, Low-Beer D, et al. Requirements for
24 global elimination of hepatitis B: a modelling study. *Lancet Infect Dis* 2016;16:1399–408.
- 25
26 15. Awowole IO, Kuti O, Asaleye CM, Badejoko OO, Bola-Oyebamiji SB, Olatunji RB, et al.
27 Normative References and Clinical Correlates of Fetal Umbilical Artery Doppler Indices in
28 Southwestern Nigeria. *Int J Gynaecol Obstet.* 2020;151:134-40.
- 29
30 16. Kuti O, Awowole IO, Okunola TO. Audit of stillbirths in a Nigerian teaching hospital.
31 *Trop J Obstet Gynaecol.* 2017;34(3):188-94.
- 32
33 17. World Health Organization. Prevention of mother-to-child transmission of hepatitis B
34 virus: guidelines on antiviral prophylaxis in pregnancy. Geneva: World Health Organization; 2020.
- 35
36 18. Hou J, Cui F, Ding Y, Dou X, Duan Z, Han G et al. Management Algorithm for Interrupting
37 Mother-to-Child Transmission of Hepatitis B Virus. *Clinical Gastroenterology and Hepatology,*
38 2019; 17: 1929 – 1936.

Figure Legend

Figure 1: Algorithm for HBsAg screening of pregnant women and hepatitis B birth dose vaccination of exposed babies.

Table 1: Causes of perinatal deaths among women with hepatitis B infection in pregnancy at OAUTHC.

Cause	Perinatal mortality N = 11		Total
	Stillbirths	Neonatal Deaths	Frequency (%)
Antepartum haemorrhage	2	1	3 (27.3)
Eclampsia	1	1	2 (18.2)
Obstructed labour*	1	1	2 (18.2)
Out-of-facility delivery	0	2	2 (18.2)
Fetal Growth Restriction	1	0	1 (9.1)
Unexplained	1	0	1 (9.1)
Total	6	5	11(100)

*Patients presented late to the facility after initial management at unorthodox centers.




Figure 1: Algorithm for HBsAg screening of pregnant women and hepatitis B birth dose vaccination of exposed babies

STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cohort studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	2
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	4
		(b) For matched studies, give matching criteria and number of exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	5
Bias	9	Describe any efforts to address potential sources of bias	5
Study size	10	Explain how the study size was arrived at	NA
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	NA
		(c) Explain how missing data were addressed	6
		(d) If applicable, explain how loss to follow-up was addressed	7
		(e) Describe any sensitivity analyses	NA
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6
		(b) Give reasons for non-participation at each stage	6
		(c) Consider use of a flow diagram	Yes
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6
		(b) Indicate number of participants with missing data for each variable of interest	6
		(c) Summarise follow-up time (eg, average and total amount)	6
Outcome data	15*	Report numbers of outcome events or summary measures over time	6
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	NA
		(b) Report category boundaries when continuous variables were categorized	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	6
Discussion			
Key results	18	Summarise key results with reference to study objectives	7
Limitations			
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	7
Generalisability	21	Discuss the generalisability (external validity) of the study results	8
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	10

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.